首页> 外文期刊>American Journal of Kidney Diseases: The official journal of the National Kidney Foundation >Renal vascular endothelial function in hypertensive patients with type 2 diabetes mellitus.
【24h】

Renal vascular endothelial function in hypertensive patients with type 2 diabetes mellitus.

机译:高血压2型糖尿病患者的肾血管内皮功能

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Basal nitric oxide (NO) activity has a pivotal role in the regulation of glomerular hemodynamics, and in animal experiments, its alteration has been associated with morphological changes characteristic of diabetic nephropathy. STUDY DESIGN: Prospective observational-study during a mean follow-up of 2.1 years. SETTING & PARTICIPANTS: 66 hypertensive patients (aged 30 to 80 years) with type 2 diabetes and estimated glomerular filtration rate (GFR) greater than 80 mL/min/1.73 m(2) with normoalbuminuria or microalbuminuria. PREDICTOR: Mean arterial pressure during follow-up during treatment with telmisartan or ramipril for 9 weeks, followed by treatment according to the discretion of the individual primary care physician. OUTCOMES & MEASUREMENTS: Renal vascular resistance, renal plasma flow, GFR, and change in renal plasma flow in response to infusion of the NO synthase inhibitor N-monomethyl-L-arginine as an indicator of basal NO activity in the renal vasculature. RESULTS: 50 of 66 patients could be reexamined. At follow-up, mean arterial pressure decreased from 106 +/- 9.1 to 100 +/- 11 mm Hg (P < 0.001). Body mass index and hemoglobin A(1c) levels were unaltered. Renal vascular resistance decreased (from 128 +/- 44 to 103 +/- 30 mm Hg/mL/min/1.73 m(2); P < 0.001), renal plasma flow increased (from 490 +/- 133 to 589 +/- 154 mL/min/1.73 m(2); P < 0.001), and GFR did not change (113 +/- 22 versus 116 +/- 26 mL/min/1.73 m(2); P = 0.4) during follow-up. The decrease in renal plasma flow in response to N-monomethyl-l-arginine infusion was more pronounced at follow-up (-56.7 +/- 39 versus -73.4 +/- 48 mL/min/1.73 m(2); P = 0.02), indicating improved basal NO activity. After adjustment for possible confounders, patients with a marked decrease in mean arterial pressure showed more improved basal NO activity during follow-up than those with a less pronounced decrease in mean arterial pressure (P = 0.04). LIMITATIONS: Patients were treated according to the discretion of the individual primary care physician. CONCLUSIONS: During follow-up, renal vascular resistance, renal plasma flow, and renal endothelial function (indicated by basal NO activity) improved. Better blood pressure control was associated with improved endothelial function of the renal vasculature, thereby potentially mediating the changes in renal hemodynamics.
机译:背景:基础一氧化氮(NO)活性在调节肾小球血流动力学中起着关键作用,在动物实验中,其改变与糖尿病性肾病的形态学改变有关。研究设计:平均随访2.1年的前瞻性观察研究。地点和参与者:66例2型糖尿病高血压患者,估计肾小球滤过率(GFR)大于80 mL / min / 1.73 m(2),伴有正常白蛋白尿或微量白蛋白尿。预测:替米沙坦或雷米普利治疗9周后,在随访期间的平均动脉压,然后根据个体初级保健医生的判断进行治疗。结果与测量:输注一氧化氮合酶抑制剂N-单甲基-L-精氨酸后,肾血管阻力,肾血浆流量,肾小球滤过率(GFR)和肾血浆流量发生变化,作为肾血管中基础NO活性的指标。结果:66例患者中有50例可以重新检查。随访时,平均动脉压从106 +/- 9.1毫米汞柱降低到100 +/- 11毫米汞柱(P <0.001)。体重指数和血红蛋白A(1c)水平未改变。肾血管阻力降低(从128 +/- 44降至103 +/- 30 mm Hg / mL / min / 1.73 m(2); P <0.001),肾血浆流量增加(从490 +/- 133达到589 + / -154 mL / min / 1.73 m(2); P <0.001),并且在随访期间GFR不变(113 +/- 22对116 +/- 26 mL / min / 1.73 m(2); P = 0.4) -向上。随访时,响应N-单甲基-1-精氨酸输注的肾血浆流量减少更为明显(-56.7 +/- 39与-73.4 +/- 48 mL / min / 1.73 m(2); P = 0.02),表明基础NO活性有所提高。在对可能的混杂因素进行调整之后,平均动脉压显着降低的患者在随访期间显示出的基础NO活性比平均动脉压显着降低的患者改善了更多(P = 0.04)。局限性:根据个体初级保健医生的判断对患者进行了治疗。结论:在随访过程中,肾血管阻力,肾血浆流量和肾内皮功能(以基础NO活性表示)均得到改善。更好的血压控制与改善的肾血管内皮功能有关,从而潜在地介导了肾血流动力学的变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号